Skip to content
Home
Our Science
Pipeline & Assets
Team & Investors
Careers
News & Resources
Connect
News
& Resources
Featured Stories
Siren Biotechnology Announces FDA Clearance of First IND, Advancing Company to Clinical Stage
Read More
GlobeNewswire
Siren Biotechnology Publishes Foundational AAV Immuno-Gene Therapy Data and Announces Presentations at ASGCT 2026
Read More
Siren Biotechnology Receives FDA Fast Track Designation for SRN-101 for the Treatment of Recurrent High-Grade Glioma
Read More
News
Patient Resources
Videos
Publications & Presentations
All
Media Coverage
Press Releases
Media Coverage
|
Posted on 5.17.23
Nicole Paulk’s Siren Bio is building a gene therapy delivery vehicle against cancer
Read More
Media Coverage
|
Posted on 5.17.23
ASGCT News: Siren Biotechnology Hails Universal Gene Therapy for Oncology
Read More
Media Coverage
|
Posted on 5.17.23
A new startup looks to turn the workhorse of gene therapy against cancer
Read More
Press Releases
|
Posted on 5.17.23
Siren Biotechnology Unveils Preclinical Data for Universal AAV Immuno-Gene Therapy for Cancer, a Novel Modality that Combines AAV Gene Therapy and Cytokine Immunotherapy
Read More
Press Releases
|
Posted on 5.17.23
Siren Biotechnology Launches to Pioneer Universal AAV Immuno-Gene Therapy for Cancer
Read More
Media Coverage
|
Posted on 3.2.23
Nicole Paulk is named one of the Bay Area’s next generation of life science researchers
Read More
Media Coverage
|
Posted on 12.5.22
Insights from Nicole Paulk on the latest gene therapy for hemophilia B
Read More
Media Coverage
|
Posted on 8.25.22
Siren’s Founder & CEO, Nicole Paulk, speaks on pricing and access for gene therapies
Read More
Media Coverage
|
Posted on 10.1.21
Hear from Nicole Paulk on XLMTM gene therapy
Read More
Media Coverage
|
Posted on 8.12.21
Nicole Paulk on gene therapy’s next steps
Read More
1
…
3
4
5
6
